当前位置： SCI文献检索 > HIV MEDICINE期刊下所有文献 > Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

Abstract：

OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (PLHIV) in two different settings in South Africa. METHODS:A cross-sectional analysis was conducted comparing data from the Ndlovu Cohort Study in the Limpopo Province (group 1) and from three clinical trials in Johannesburg (group 2). The association between demographics, conventional CVD risk factors, HIV-related factors and CIMT in groups 1 and 2 was analysed with two separate multivariable linear regression models. RESULTS:Group 1 consisted of 826 participants (mean age 42.2 years) and mean (± standard deviation) CIMT was 0.626 ± 0.128 mm. In this group, sex, age, body mass index (BMI), cholesterol, glucose and antiretroviral therapy (ART) duration (β = 0.011 mm per 5 years; P = 0.02) were associated with higher CIMT. There were positive interactions between age and ART duration and age and cholesterol. Group 2 consisted of 382 participants (mean age 39.5 years) and mean (± standard deviation) CIMT was 0.560 ± 0.092 mm. In this group, only sex, education level, BMI and cholesterol were associated with higher CIMT, albeit with weaker associations than in group 1. CONCLUSIONS:Conventional CVD risk factors were the main drivers of CIMT. The impact of some of these risk factors appeared to increase with age. Differences in sample size, age and viral suppression might explain why an effect of ART was observed in group 1 but not in group 2.

journal_name

HIV Med

journal_title

HIV medicine

authors

Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

doi

10.1111/hiv.12831

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

386-396

issue

6

eissn

1464-2662

issn

1468-1293

journal_volume

21

pub_type

杂志文章

相关文献

HIV MEDICINE文献大全
  • Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests underestimate hepatitis prevalence among HIV-infected patients.

    abstract：OBJECTIVES:In the case of coinfection with HIV and hepatitis B virus (HBV) and/or hepatitis C virus (HCV), hepatic disease progression is often accelerated, with higher rates of liver cirrhosis and liver-related mortality. We aimed to evaluate the performance of the rapid tests used routinely to detect HBV surface anti...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12158

    authors： Hønge B,Jespersen S,Medina C,Té D,da Silva Z,Ostergaard L,Laursen A,Wejse C,Krarup H,Erikstrup C,Bissau HIV cohort study group.

    更新日期：2014-10-01 00:00:00

  • Merkel cell carcinoma and multiple basal cell carcinoma in an African albino woman with HIV infection.

    abstract：:A 25-year-old HIV-infected African albino woman developed an aggressive Merkel cell carcinoma on her face and at least 10 basal cell carcinomas, mainly on sun-exposed parts of her body. HIV infection, immune deficiency and sun exposure are known risk factors for the development of Merkel cell carcinoma. Chemotherapy a...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2004.00252.x

    authors： Colebunders R,Bottieau E,Van den Brande J,Colpaert C,Van Marck E

    更新日期：2004-11-01 00:00:00

  • Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada.

    abstract：OBJECTIVES:Outbreaks of shigellosis have been documented in men who have sex with men (MSM), associated with interpersonal transmission and underlying HIV infection. We observed a rise in Shigella flexneri isolates identified in a downtown tertiary-care hospital laboratory located within the city centre community healt...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12191

    authors： Wilmer A,Romney MG,Gustafson R,Sandhu J,Chu T,Ng C,Hoang L,Champagne S,Hull MW

    更新日期：2015-03-01 00:00:00

  • CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.

    abstract：OBJECTIVES:The nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz undergoes phase I metabolism by the cytochrome P450 enzyme, CYP2B6. Previous studies outside of the United Kingdom have shown associations between the CYP2B6 polymorphism G516T and increased toxicity. This study aimed to develop a CYP2B6 G51...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2009.00718.x

    authors： Powers V,Ward J,Gompels M

    更新日期：2009-09-01 00:00:00

  • Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.

    abstract：OBJECTIVES:Effective HIV therapy reflects suppression of plasma HIV RNA levels below assay detection thresholds, although lower levels of "residual viraemia" have also been demonstrated over extended periods of effective antiretroviral treatment. Here we examine the determinants of HIV RNA suppression below the standar...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12323

    authors： McKinnon E,Castley A,Payne L,Pummer S,Nolan D

    更新日期：2016-08-01 00:00:00

  • Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease.

    abstract：BACKGROUND:Recent studies in hospitalized patients with community-acquired pneumonia have found a lower risk of bacteraemia and better clinical outcomes in patients who had previously received the 23-valent pneumococcal polysaccharide vaccine (PPV) in comparison with unvaccinated individuals. The aim of this study was ...

    journal_title：HIV medicine

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1468-1293.2009.00695.x

    authors： Imaz A,Falcó V,Peñaranda M,Jordano Q,Martínez X,Nadal C,Curran A,Planes AM,Dalmau D,Ribera E,Riera M,Ruiz de Gopegui E,Pahissa A

    更新日期：2009-07-01 00:00:00

  • Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy.

    abstract：OBJECTIVES:Different experimental approaches have shown that, despite plasma viral loads under the threshold of detection, HIV-1 frequently continues to replicate in patients receiving potent antiretroviral therapy. However, whether this low-grade viral replication is sufficient for the generation of new major quasispe...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1046/j.1468-1293.2000.00030.x

    authors： Birk M,Aleman S,Visco-Comandini U,Sönnerborg A

    更新日期：2000-10-01 00:00:00

  • Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

    abstract：OBJECTIVES:Efforts are needed to improve informed consent of participants in research. The Strategic Timing of AntiRetroviral Therapy (START) study provides a unique opportunity to study the effect of length and complexity of informed consent documents on understanding and satisfaction among geographically diverse part...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/hiv.12230

    authors： Denning E,Sharma S,Smolskis M,Touloumi G,Walker S,Babiker A,Clewett M,Emanuel E,Florence E,Papadopoulos A,Sánchez A,Tavel J,Grady C,International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Grou

    更新日期：2015-04-01 00:00:00

  • HIV testing uptake among female sex workers and men who have sex with men in Tbilisi, Georgia.

    abstract：OBJECTIVES:The aim of the study was to investigate HIV testing practice among female sex workers (FSWs) and men who have sex with men (MSM) in Tbilisi, Georgia and to identify determinants of never testing behaviour among MSM. METHODS:Data obtained in two rounds of bio-behavioural surveys among FSWs (2006 and 2009) an...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12065

    authors： Tsereteli N,Chikovani I,Chkhaidze N,Goguadze K,Shengelia N,Rukhadze N

    更新日期：2013-10-01 00:00:00

  • Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

    abstract：OBJECTIVES:The aim of the study was to compare the neuropsychiatric safety and tolerability of rilpivirine (TMC278) vs. efavirenz in a preplanned pooled analysis of data from the ECHO and THRIVE studies which compared the safety and efficacy of the two drugs in HIV-1 infected treatment naïve adults. METHODS:ECHO and T...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/hiv.12012

    authors： Mills AM,Antinori A,Clotet B,Fourie J,Herrera G,Hicks C,Madruga JV,Vanveggel S,Stevens M,Boven K,ECHO and THRIVE study groups.

    更新日期：2013-08-01 00:00:00

  • How reliable is an undetectable viral load?

    abstract：OBJECTIVES:An article by the Swiss AIDS Commission states that patients with stably suppressed viraemia [i.e. several successive HIV-1 RNA plasma concentrations (viral loads, VL) below the limits of detection during 6 months or more of highly active antiretroviral therapy (HAART)] are unlikely to be infectious. Questio...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2009.00714.x

    authors： Combescure C,Vallier N,Ledergerber B,Cavassini M,Furrer H,Rauch A,Battegay M,Bernasconi E,Vernazza P,Hirschel B,Swiss HIV Cohort Study.

    更新日期：2009-09-01 00:00:00

  • Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy.

    abstract：OBJECTIVE:To measure the evolution of proviral HIV-1 DNA levels in patients receiving highly active antiretroviral therapy (HAART) compared to those treated with HAART plus interleukin-2 (IL-2) and hydroxyurea. DESIGN:Prospective randomised trial. METHODS:Twenty-two HIV-1 infected patients were randomly assigned to a...

    journal_title：HIV medicine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1468-1293.2001.00065.x

    authors： Lafeuillade A,Poggi C,Chadapaud S,Hittinger G,Khiri H,Halfon P

    更新日期：2001-07-01 00:00:00

  • Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.

    abstract：OBJECTIVES:People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug-drug interactions (DDIs) in PWHIV. METHODS:The Climate-HIV electronic recording system was used to cross-sectionally analyse records from PWHIV aged ≥ 18 years attending four UK HIV units with a curr...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12879

    authors： Okoli C,Schwenk A,Radford M,Myland M,Taylor S,Darley A,Barnes J,Fox A,Grimson F,Reeves I,Munshi S,Croucher A,Boxall N,Benn P,Paice A,van Wyk J,Khoo S

    更新日期：2020-09-01 00:00:00

  • Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.

    abstract：OBJECTIVES:Virological failure on first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based treatment regimens has become a problem in HIV-infected children on long-term antiretroviral therapy (ART). Protease inhibitor (PI)-based regimens are therefore often given to children failing NNRTI-based regimens. ...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2012.01061.x

    authors： Wattanutchariya N,Sirisanthana V,Oberdorfer P

    更新日期：2013-04-01 00:00:00

  • Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study.

    abstract：OBJECTIVE:Data from observational cohorts may be influenced by population structure and loss to follow-up (LTFU). Quality of care may be associated with participation in cohort networks. We aimed to study the participation, characteristics and retention rates of immigrants in the Swiss HIV Cohort Study (SHCS). METHODS...

    journal_title：HIV medicine

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1468-1293.2011.00949.x

    authors： Thierfelder C,Weber R,Elzi L,Furrer H,Cavassini M,Calmy A,Bernasconi E,Gutmann C,Ledergerber B,Swiss HIV Cohort Study Group.

    更新日期：2012-02-01 00:00:00

  • The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000.

    abstract：OBJECTIVE:To document the demographic changes in new HIV diagnoses at the Royal Free Hospital, London, UK, between 1994 and 2000. DESIGN:Retrospective case note review. METHODS:Data were extracted from the Royal Free HIV database identifying new diagnoses for 1994, 1997 and 2000. All case notes were reviewed and pati...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1046/j.1468-1293.2002.00103.x

    authors： Barry SM,Lloyd-Owen SJ,Madge SJ,Cozzi-Lepri A,Evans AJ,Phillips AN,Johnson MA

    更新日期：2002-04-01 00:00:00

  • Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.

    abstract：OBJECTIVES:Direct-acting antiviral agents (DAAs) have become the standard of care for the treatment of chronic hepatitis C virus (HCV) infection. We aimed to assess treatment uptake and efficacy in routine clinical settings among HIV/HCV coinfected patients after the introduction of the first generation DAAs. METHODS:...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12269

    authors： Schaerer V,Haubitz S,Kovari H,Ledergerber B,Ambrosioni J,Cavassini M,Stoeckle M,Schmid P,Decosterd L,Aouri M,Böni J,Günthard HF,Furrer H,Metzner KJ,Fehr J,Rauch A,Swiss HIV Cohort Study.

    更新日期：2015-11-01 00:00:00

  • Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

    abstract：OBJECTIVES:Pregnant women experience physiological changes during pregnancy that can have a significant impact on antiretroviral pharmacokinetics. Ensuring optimal plasma concentrations of antiretrovirals is essential for maternal health and to minimize the risk of vertical transmission. Here we describe atazanavir/rit...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12164

    authors： Else LJ,Jackson V,Brennan M,Back DJ,Khoo SH,Coulter-Smith S,Lambert JS

    更新日期：2014-11-01 00:00:00

  • Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy.

    abstract：:We report the case of an asthmatic man with HIV infection who was initially diagnosed with HIV treatment-associated lipodystrophy. Further investigations showed he had Cushing's syndrome secondary to 1600 microg of budesonide dry powder inhaler. Cushing's syndrome has not been reported previously on this normal dose o...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1046/j.1468-1293.2001.00058.x

    authors： le Roux CW,Beckles MA,Besser GM,Pinching AJ,Davison AG

    更新日期：2001-04-01 00:00:00

  • Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.

    abstract：BACKGROUND:AIDS-related lymphoma (ARL) remains the main cause of AIDS-related deaths in the combined antiretroviral therapy (cART) era. Although most ARLs are associated with the Epstein-Barr virus (EBV), whether patients with high EBV burden are more at risk of developing ARL is unknown. This study investigated the re...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2012.00998.x

    authors： Leruez-Ville M,Seng R,Morand P,Boufassa F,Boue F,Deveau C,Rouzioux C,Goujard C,Seigneurin JM,Meyer L

    更新日期：2012-09-01 00:00:00

  • Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

    abstract：BACKGROUND:More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005. DESIGN AND METHODS:In 2005, 34 departments prospectively recorded all dea...

    journal_title：HIV medicine

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1468-1293.2008.00686.x

    authors： Rosenthal E,Salmon-Céron D,Lewden C,Bouteloup V,Pialoux G,Bonnet F,Karmochkine M,May T,François M,Burty C,Jougla E,Costagliola D,Morlat P,Chêne G,Cacoub P,Mortavic\/Mortalité 2005 Study Group.

    更新日期：2009-05-01 00:00:00

  • High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey.

    abstract：BACKGROUND:Southern African countries have borne the brunt of the HIV/AIDS pandemic. Monitoring epidemiological dynamics is critical to identify the populations at greatest risk of infection and to guide control strategies. METHODS:A cross-sectional community-based study to determine age- and sex-specific HIV prevalen...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2012.01018.x

    authors： González R,Munguambe K,Aponte J,Bavo C,Nhalungo D,Macete E,Alonso P,Menéndez C,Naniche D

    更新日期：2012-11-01 00:00:00

  • The case for indicator condition-guided HIV screening.

    abstract：:One-half of the estimated 2.5 million people who now live with HIV in the World Health Organization (WHO) European Region are still diagnosed late. A central question is which clinical scenarios should trigger an HIV test recommendation in order to avoid late presentation. Drawing on the work of the HIV Indicator Dise...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12022

    authors： Lazarus JV,Hoekstra M,Raben D,Delpech V,Coenen T,Lundgren JD,HIV in Europe Initiative Steering Committee.

    更新日期：2013-08-01 00:00:00

  • Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

    abstract：BACKGROUND:The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy wit...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1468-1293.2009.00752.x

    authors： Ghosn J,Flandre P,Cohen-Codar I,Girard PM,Chaix ML,Raffi F,Dellamonica P,Ngovan P,Norton M,Delfraissy JF,MONARK Study Group.

    更新日期：2010-02-01 00:00:00

  • Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study.

    abstract：OBJECTIVES:Few studies have explored the optimal dosing for efavirenz in individuals from China. We investigated plasma efavirenz concentrations and their association with efficacy and tolerance of efavirenz 600 mg daily in Chinese HIV-infected adults. METHODS:An analysis was performed using plasma samples from 455 pa...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12607

    authors： Guo F,Cheng X,Hsieh E,Du X,Fu Q,Peng W,Li Y,Song X,Routy JP,Li T

    更新日期：2018-05-15 00:00:00

  • Financial stress is associated with reduced treatment adherence in HIV-infected adults in a resource-rich setting.

    abstract：OBJECTIVES:Financial stress has been identified as a barrier to antiretroviral adherence, but only in resource- limited settings. Almost half of HIV-infected Australian adults earn no regular income and, despite highly subsidised antiretroviral therapy and universal health care, 3% of HIV-infected Australians cease ant...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2012.01034.x

    authors： McAllister J,Beardsworth G,Lavie E,MacRae K,Carr A

    更新日期：2013-02-01 00:00:00

  • Knowledge of their children's HIV status in HIV-positive mothers attending a genitourinary medicine clinic in the UK.

    abstract：OBJECTIVES:To determine whether HIV-infected mothers knew the HIV status of their children, enabling the offer of targeted testing of children at risk. METHODS:All HIV-positive women attending the genitourinary medicine clinic at a district general hospital in the United Kingdom were asked whether they had children an...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2008.00556.x

    authors： Eisenhut M,Sharma V,Kawsar M,Balachandran T

    更新日期：2008-04-01 00:00:00

  • Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.

    abstract：OBJECTIVES:Antiretroviral therapy (ART) has been associated with unfavourable lipid profile changes and increased risk of cardiovascular disease (CVD). With a growing population on ART in South Africa, there has been concern about the increase in noncommunicable diseases such as CVD. We determined risk factors associat...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12495

    authors： Jamieson L,Evans D,Brennan AT,Moyo F,Spencer D,Mahomed K,Maskew M,Long L,Rosen S,Fox MP

    更新日期：2017-09-01 00:00:00

  • The association of adiposity with kidney function decline among HIV-infected adults: findings from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) study.

    abstract：OBJECTIVES:The aim of the study was to investigate the association of adiposity with longitudinal kidney function change in 544 HIV-infected persons in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) cohort over 5 years of follow-up. METHODS:The regional distribution of muscle and adipose ...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12196

    authors： Malkina A,Scherzer R,Shlipak MG,Bacchetti P,Tien PC,Grunfeld C,Kosmiski L,Peralta CA

    更新日期：2015-03-01 00:00:00

  • An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.

    abstract：OBJECTIVES:Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is a drug that is frequently included in highly active antiretroviral therapy for treatment of HIV infection. Decreased bioavailability and increased toxicity limit its use. We report a formulation of efavirenz-loaded lactoferrin nanoparticle...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12475

    authors： Kumar P,Lakshmi YS,Kondapi AK

    更新日期：2017-08-01 00:00:00